A major challenge to the success of cellular therapies is the ability to isolate large quantities of a desired population of cells safely, efficiently and inexpensively, thereby allowing for their use in the treatment of disease, particularly cancer, infectious diseases and autoimmune conditions. Current limitations revolve around the design of current technology that can only separate cells from peripheral blood or expand them through batch culture.

t. Breeders Inc. is working on a solution by providing a production system for highly pure, well-characterized populations of stem cells to deliver long-term, cancer-free engraftment through its Breeder bioreactor technology.